Short Description Einstein geroscientist steering the first FDA‑guided longevity trial (TAME).
Description Dr. Nir Barzilai studies centenarians and insulin signaling, identifying protective CETP and IGF mutations. He leads the Targeting Aging with Metformin (TAME) trial, aiming to show multi‑disease risk reduction by addressing aging biology. Author of 'Age Later', Barzilai bridges academic geroscience with policy advocacy in Washington, D.C.